5 mg Tadalafil + Placebo + 0.2 mg Tamsulosin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Benign Prostate Hyperplasia
Conditions
Benign Prostate Hyperplasia, Erectile Dysfunction
Trial Timeline
Sep 1, 2013 → Dec 1, 2015
NCT ID
NCT01937871About 5 mg Tadalafil + Placebo + 0.2 mg Tamsulosin
5 mg Tadalafil + Placebo + 0.2 mg Tamsulosin is a phase 3 stage product being developed by Eli Lilly for Benign Prostate Hyperplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT01937871. Target conditions include Benign Prostate Hyperplasia, Erectile Dysfunction.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01937871 | Phase 3 | Completed |
Competing Products
20 competing products in Benign Prostate Hyperplasia